ArticleFrontiers in bioinformatics2025
Role of histone-lysine N-methyltransferase 2D (KMT2D) in MEK-ERK signaling-mediated epigenetic regulation: a phosphoproteomics perspective.
Article in Frontiers in bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Phosphoproteomics Data-Driven Integrative Analysis of Autophosphorylation Sites in the Human Kinome.International journal of molecular sciences · 2026Article
- Deciphering Site-Specific Regulatory Networks of the Kinesin Protein KIF21A Through Integrative Phosphoproteomic Analysis.International journal of molecular sciences · 2026Article
- Phosphorylation-dependent regulation of Eleven Lysine Rich Leukemia (ELL) uncovered by quantitative global phosphoproteomic analysis.Molecular genetics and genomics : MGG · 2026Article
- Dissecting the Phospho-Regulatory Landscape of Protein Kinase N1 (PKN1) and Its Downstream Signaling: Functional Insights into the Activity-Dependent and Disease-Relevant Phosphosites.International journal of molecular sciences · 2026Article
- Genomic innovations in cancer prevention, diagnosis, prognosis and precision therapeutics.Frontiers in genetics · 2026Review
- Integrative analysis of YTHDC1 phosphoproteome unveils its phosphomodulatory network linked to splicing and tumorigenesis.Frontiers in bioinformatics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Histone-lysine N-methyltransferase 2D (KMT2D) is an H3K4 methyltransferase and a potential tumor suppressor with a crucial role in regulating gene expression. Its dysregulation has been implicated in developmental disorders and several types of cancers. Despite this, the molecular mechanisms that govern its activity remain largely elusive. Among these, post-translational modifications, especially phosphorylation, serve as an essential regulator, fine-tuning KMT2D stability, localization and functional interactions for maintaining cellular homeostasis. With over 173 phosphorylation sites reported, KMT2D is significantly regulated by kinases and exploring its phospho-regulatory network based on targeted Methods: We systematically curated and integrated the global phosphoproteomic datasets, along with their corresponding experimental conditions, to comprehensively identify the phosphorylation events reported for KMT2D. The site exhibiting the highest frequency of detection across these datasets is considered the predominant phosphorylation site. To investigate its functional significance, we analyzed the proteins and their phosphorylation sites that are differentially co-regulated with the predominant site, as well as its associated upstream kinases and interacting proteins. Results: Among the 173 reported phosphorylation sites representing KMT2D, Serine 2274 (S2274) emerged as the predominant site being detected in over 42% of diverse mass spectrometry-based phosphoproteomics datasets. This site lies within one of KMT2D's unique " Discussion: This study delineates the phosphoregulatory network of KMT2D, positioning it as a dynamic epigenetic effector modulated by MEK-ERK signaling, with broader implications for cancer and developmental disorders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.